静脉注射钆基对比剂对乳腺扩散张量成像的影响
前瞻性队列纳入26例BI-RADS 0、4、5或6类女性,在3T乳腺MRI注射钆基对比剂前后行扩散张量成像。注射后乳腺癌病灶扩散系数、平均扩散率和b0信号强度显著降低,但各参数诊断AUC在注射前后无显著差异;作者认为无对比剂扩散测量应优先。
要点
- 乳腺癌在λ1图注射前后均可见,注射后病灶扩散系数、平均扩散率及b0信号强度显著降低(p<0.05)。
- 正常组织与良性病灶的扩散张量成像参数在注射前后无显著变化。
- 除λ3外,各参数注射前后诊断AUC无显著差异。
核心结论
- 注射钆基对比剂前后使用扩散张量成像的诊断准确性等效,尽管扩散张量成像参数值发生变化。
- 对比剂增强标准化存在局限,作者认为无对比剂扩散测量应优先。
研究设计与样本
- 前瞻性队列研究,纳入26例BI-RADS 0、4、5或6类女性,行3T乳腺MRI。
- 在钆基对比剂注射前及注射后立即序贯行扩散张量成像,使用专用扩散张量成像软件获得各向扩散系数、平均扩散率和最大各向异性的参数图。
- 参考标准为病理结果:58%为癌症(13例浸润性导管癌、2例导管原位癌),42%为良性或正常结果。
关键影像表现/征象
- 所有乳腺癌在注射前后λ1图上均可视觉检出。
- 注射前λ1图测得癌灶平均大小15.3 mm(范围3.3-72.3 mm),注射后17.3 mm(范围3.9-71.0 mm),差异无统计学显著意义。
- 注射后癌灶各向扩散系数、平均扩散率和b0信号强度较注射前显著降低(p<0.05),最大各向异性无变化。
- 正常组织和良性病灶的上述参数在注射后无显著变化。
诊断标准与关键数值
- 注射前各参数诊断AUC范围为0.735至0.985,注射后范围为0.867至0.990。
- 除λ3外,各参数注射前后AUC无统计学显著差异。
临床应用与阅片要点
- 注射后乳腺癌扩散张量成像参数值降低,但诊断准确性等效,阅片时需注意参数值变化。
- 作者认为无对比剂扩散测量应优先。
局限性
- 对比剂增强标准化存在局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE. The purpose of this study was to quantify changes in diffusion-tensor imaging (DTI) parameters before and after IV administration of a gadolinium-based contrast agent (GBCA) and explore the influence of those parameters on breast cancer diagnosis. SUBJECTS AND METHODS. A prospective cohort of 26 women with BI-RADS categories 0, 4, 5, or 6 underwent 3-T breast MRI with sequential DTI before GBCA administration and immediately after. Quantitative image analysis using dedicated DTI software yielded parametric DTI maps of each directional diffusion coefficient (DDC), mean diffusivity, and maximal anisotropy of the lesions and normal tissue. The color maps were evaluated and the lesion DTI parameters were compared before and after GBCA administration using appropriate statistical tests. RESULTS. Of the cohort, 58% had cancer (13 infiltrating ductal carcinoma, two ductal carcinoma in situ) and 42% had benign or normal results. All breast cancers were visually detected in the DDC λ1 maps before and after GBCA administration. Mean cancer size derived from λ1 maps before GBCA administration was 15.3 mm (range, 3.3-72.3 mm), and was not statistically significantly different from the size derived after GBCA administration of 17.3 mm (range, 3.9-71.0 mm). After GBCA administration, the cancers exhibited statistically significantly lower DDCs, mean diffusivity, and b0 intensity (p < 0.05), and no change in maximal anisotropy compared with before GBCA administration, whereas these parameters in normal and benign lesions did not change significantly after GBCA administration. The mean AUC values before and after GBCA administration, ranging from 0.735 to 0.985 and from 0.867 to 0.990, respectively, were not statistically significantly different for all parameters aside from λ3. CONCLUSION. Diagnostic accuracy using DTI was equivalent before and after GBCA administration, despite a change in the values of the DTI parameters. However, the limitations in standardization of contrast enhancement implies that unenhanced diffusion measurements should be preferred.
引用
- Scaranelo AM, Degani H, Grobgeld D, et al. Effect of IV Administration of a Gadolinium-Based Contrast Agent on Breast Diffusion-Tensor Imaging. AJR Am J Roentgenol. 2020. PMID: 32755227. doi:10.2214/AJR.19.22085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。